Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Bristol-Myers Squibb Co. (BMY) One of the Best Companies in America?

Page 1 of 2

Missed it by this much. That’s how it goes some times.

The Motley Fool recently published its list of The 25 Best Companies in America and while Bristol-Myers Squibb Co. (NYSE:BMY)made the initial cut down from 1,700 public companies to about 40, it failed to make the final cut.

For having such a long name and a history that dates back to 1858, Bristol-Myers Squibb is surprisingly smaller than most of its pharmaceutical peers. Quite a few younger big biotechs — Celgene Corporation (NASDAQ:CELG), Gilead Sciences, Inc. (NASDAQ:GILD), and Amgen, Inc. (NASDAQ:AMGN) — have market caps larger than Bristol-Myers.

Bristol Myers Squibb Co. (NYSE:BMY)While bigger is often better because it helps with profit margins, I like the smaller, more-focused Bristol Myers Squibb Co. (NYSE:BMY).

A few years ago, Bristol-Myers decided to slim down and focus exclusively on drug development. The company spun off its baby formula business, Mead Johnson Nutrition CO (NYSE:MJN), and sold off quite a few other auxiliary businesses while expanding its drug development through acquisitions to fill its pipeline.

That forward-thinking attitude has earned it a nomination for the Fool’s top 25 best-run companies.

The case for Bristol Myers Squibb Co. (NYSE:BMY)
Drug development is risky business, but Bristol-Myers has protected investors by sharing that risk with other drugmakers. Its mega blockbuster Plavix was developed with Sanofi SA (ADR) (NYSE:SNY) . Bristol-Myers’ next potential blockbuster, Eliquis, was developed with Pfizer Inc. (NYSE:PFE). The company has also established a diabetes partnership with AstraZeneca plc (ADR) (NYSE:AZN), which led to the companies jointly purchasing Amylin Pharmaceuticals.

Developing drugs with a partner cuts into the potential profits, but it also shields the company from major hits if the drug fails. When Bristol-Myers has gone it alone, it hasn’t been pretty. The company purchased Inhibitex for $2.5 billion only to see the lead hepatitis C drug it got in the deal fail in the clinic.

Beyond shareholders, Bristol-Meyers treats the rest of the stakeholders with equal respect.

Like most drugmakers, Bristol-Myers has a patient assistance program to help patients pay for their medication. In 2011, the company provided 250,000 patients with free medications valued at more than $450 million.

More generally, Bristol-Myers takes its corporate responsibility seriously. In 2010, it set a series of goals to be completed by 2015, including reducing total energy use and greenhouse gas emissions by 15% and to reduce water use by 10%.

According to reviews on Glassdoor, only 68% of employees would recommend working at Bristol-Myers to a friend, although interestingly 91% approve of CEO Lamberto Andreotti. Many of the reviews complain that it’s difficult to advance in the company. Apparently everyone wants to eventually have Andreotti’s job, but doesn’t feel like that’s possible. Something for the company to work on, for sure.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!